Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Essential Drug List To Be Released In Two Phases

This article was originally published in PharmAsia News

Executive Summary

According to authoritative sources, China will adopt a two-step approach for its national essential drug list release: a mini-list comprising 178 western medicines and 78 patent TCMs will be issued soon, while an enriched list is expected to come out after Aug. 16. China's Ministry of Health, National Development and Reform Commission and Ministry of Human Resources and Social Security have jointly discussed and confirmed the first batch of documents for healthcare reform, including the essential drug list, essential drug pricing, as well as tender and purchase specifics. Relevant administrations have selected Class I medical care institutions to pilot the mini-list. Another list may leave 5 percent of total medicines to local governments for selection and adjustment; however, the issue of dealing with specific drugs is still outstanding. (Click here for more - Chinese Language)

You may also be interested in...



BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC

The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.

BIO 2021 Notebook: Best Practices For Business Development

The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.

Blueprint Prepares To Take On Novartis In Advanced Systemic Mastocytosis

The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.

UsernamePublicRestriction

Register

SC072040

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel